EUCTR2006-001517-15-IT进行中（未招募）不适用
Italian multicenter phase II trial using Fotemustine plus Bevacizumab as first-line therapy in metastatic melanoma. - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histological or cytological confirmed cutaneous malignant melanoma 2. Advanced, inoperable nonchoroidal stage IV melanoma, including unresectable regional lymphatic disease and/or extensive in transit recurrent disease 3. Age 18 4. Performance status 0-1 ECOG 5. Life-expectancy 3 months 6. Measurable and/or evaluable sites of metastases, confirmed by X-Ray, ultrasound, CT scan and NMR at least 1 mm 7. A previous IFN-based immunotherapy in adjuvant setting and/or a vaccination in metastatic setting are allowed however, a wash-out period of at least 4 weeks is requested 8. Normal blood counts ANC 1500/microL and platelet count 150,000/microL , liver function ALT, AST and alkaline phosphatase levels up to 2.5 x upper limit of the normal ranges UNL ; 8804;5 x UNL in case of liver metastases and total bilirubin 3.0 mg/ml; then, alkaline phosphatase 8804;10 x UNL in case of bone metastases and renal function BUN and creatinine levels within the normal ranges, and, in particular, creatinine clearance 50 mL/min or serum creatinine 8804;1.5 x UNL 9. INR 1.5 and APTT 1.5 x UNL 10. Urine dipstick of proteinuria 2 . Patients discovered to have 2 proteinuria on dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must demonstrate 8804;1 g of protein/24 hrs 11. Written informed consent according to the local Ethics Committee requirements 12. Patients accessibility for treatment and follow-up 13. Complete initial work-up within 4 weeks prior to the beginning of treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Prior chemotherapy and/or IFN/IL-2 based immunotherapy for metastatic disease 2. Prior investigational antiangiogenic agents 3. Prior malignancies diagnosed within the last 5 years, with the exception of cured non melanoma skin cancer or adequately treated in situ carcinoma of the cervix. 4. Pregnancy and breast-feeding. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females of childbearing potential unwilling to practice contraception during the study 5. Recent major surgery within 28 days prior to study treatment start 6. Planned radiotherapy for underlying disease 7. Clinical or radiological evidence of CNS metastases 8. Patients with known allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications 9. Other serious illness or medical condition - Serious non-healing wound or ulcer - Evidence of bleeding diathesis or coagulopathy - Uncontrolled hypertension - Congestive heart failure NYHA grade 2 , prior myocardial infarction or cerebrovascular accidents within 6 months, unstable angina, serious cardiac arrhythmia requiring medication - History of significant neurological or psychiatric disorders that would prohibit the understanding and giving of informed consent - Infections requiring i.v. antibiotics and tuberculosis under treatment for entering the trial - Active or latent autoimmune diseases a determination of anti-thyreoglobulin and antinuclear antibodies is requested for entering the trial - Ongoing treatment with aspirin 325 mg/day or other medications known to predispose to gastrointestinal ulceration - Current or recent within 10 days prior to study treatment start ongoing treatment with full-dose anticoagulants for therapeutic purpose - Active peptic ulcer, unstable diabetes mellitus, cirrhosis and other significant uncontrolled illness, which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial
研究者
相似试验
进行中（未招募）
不适用
Phase II multicenter study with Fotemustine and Temozolomide modulation in patients with metastatic melanoma (MM) - Phase II multicenter study with Fotemustine and Temozolomide in MMPatients with metastatic melanoma non pre-treated for advanced diseaseMedDRA version: 12.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2009-016487-36-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE
进行中（未招募）
1 期
An Italian multicenter trial with Temozolomide taken daily at low doses continuously in patients with well differentiated neuroendocrine neoplasia (NENs) and in a clinical frailty statusPatients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.MedDRA version: 20.0Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005393-10-ITISTITUTO EUROPEO DI ONCOLOGIA46
招募中
1 期
An Italian multicenter trial with Temozolomide taken daily at low doses continuously in patients with well differentiated neuroendocrine neoplasia (NENs) and in a clinical frailty statusPatients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.MedDRA version: 20.0Level: PTClassification code: 10057270Term: Neuroendocrine carcinoma Class: 100000004864CTIS2024-510898-24-00European Institute Of Oncology S.r.l.46
进行中（未招募）
不适用
Study to learn if 200mg test drug (Fostamatinib) helps people with Large B-Cell Lymphoma, a type of blood cancerDiffuse Large B-cell LymphomaMedDRA version: 16.1Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 100000004864EUCTR2011-005371-16-GBRigel Pharmaceuticals, Inc.60
进行中（未招募）
1 期
Furazidin for resolution or improvement of all clinical symptoms of Urinary Tract InfectionsEUCTR2020-005559-19-PLADAMED Pharma S.A.636